Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KGX105 in Advanced or Metastatic Solid Tumors
NCT07702955Phase 1Not yet recruiting
- Sponsor
- KangaBio
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of KGX105 in solid tumor (7 arms), sponsored by KangaBio. Primary endpoints: Adverse Events, Dose-Limiting Toxicities and 3 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
KGX105
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07702955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702955.